Alnylam Pharmaceuticals: Building Value from the IP Estate Harvard Case Solution & Analysis

Colour cases should be printed in color, to maximize their effectiveness. We do this by analyzing what's a fairly atypical condition today in which a single business has the capacity to secure what it perceives to be a frontier IP "estate" that blocks competitions from "practicing" in a substantial part of the field. Those who elect to sign a license deal help to fund the business's R&D and subsequently must pay a license fee that is high.

The company, meanwhile, must balance the instantaneous advantage of non-dilutive funding obtainable from the license fees vs. enabling a potential future rival. The case setting is a litigation over a seemingly arcane dilemma: whether one of the co-owners of a key patent application is correctly prosecuting the application. Understanding the issue requires pupils to progressively build up an understanding of some crucial facets of U.S. patent law. Subsequently by piecing together how its IP standing drives it and the strategy of the business, pupils can realize that the litigation represents such a high stake risk.

PUBLICATION DATE: September 01, 2010 PRODUCT #: 611009-PDF-ENG

This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS

Alnylam Pharmaceuticals: Building Value from the IP Estate Case Solution Other Similar Case Solutions like

Alnylam Pharmaceuticals: Building Value from the IP Estate

Share This